Development and Initial Validation of the Chinese Version of the Florida Surgical Questionnaire for Parkinson's Disease

Tao Wang; Yiwang Zhang; Yixin Pan; Linbin Wang; Chencheng Zhang; Jun Liu; Liuguan Bian; Bomin Sun; Dianyou Li

doi:10.1155/2020/8811435

Development and Initial Validation of the Chinese Version of the Florida Surgical Questionnaire for Parkinson's Disease

Parkinsons Dis. 2020 Dec 12:2020:8811435. doi: 10.1155/2020/8811435. eCollection 2020.

Authors

Tao Wang^{1

2}, Yiwang Zhang³, Yixin Pan^{1

2}, Linbin Wang^{1

2}, Chencheng Zhang^{1

2}, Jun Liu⁴, Liuguan Bian¹, Bomin Sun^{1

2}, Dianyou Li^{1

2}

Affiliations

¹ Department of Neurosurgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 197 Ruijin Second Road, Huangpu District, Shanghai 200025, China.
² Center for Functional Neurosurgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 197 Ruijin Second Road, Huangpu District, Shanghai 200025, China.
³ Department of Neurosurgery, 910th Hospital of People's Liberation Army, No. 180 Huayuan Road, Fengze District, Quanzhou, Fujian 362000, China.
⁴ Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, No. 197 Ruijin Second Road, Huangpu District, Shanghai 200025, China.

Abstract

Background: Deep brain stimulation (DBS) for Parkinson's disease (PD) has evolved as a well-established treatment in neurosurgery, and identifying appropriate surgical candidates could contribute to better DBS outcomes. The Florida Surgical Questionnaire for Parkinson Disease (FLASQ-PD) is a reasonable screening tool for assessing DBS candidacy in PD patients; however, a Chinese version of FLASQ-PD is needed for functional neurosurgery units in China. In this study, we translated the FLASQ-PD to Chinese and assessed its reliability and validity for Chinese PD patients.

Methods: The FLASQ-PD was translated before the study formally started. A single-center retrospective analysis of FLASQ-PD was performed at the Ruijin Hospital, affiliated with Shanghai Jiaotong University School of Medicine, between July and December 2019. The Unified Parkinson Disease Rating Scale III (UPDRS-III) was also used to assess PD patients on and off medication. All patients were evaluated for surgical candidacy by specialists.

Results: Overall, 115 PD patients, 25 with parkinsonism and six with multiple system atrophy were consecutively included. Internal consistency of the Chinese FLASQ-PD was roughly adequate (Cronbach's alpha = 0.664). There were significant differences in mean total scores of the Chinese FLASQ-PD between the diagnostic (Kruskal-Wallis H value = 37.450, p ≤ 0.001) and surgery-candidacy groups (H = 48.352, p ≤ 0.001). Drug improvements in UPDRS-III scores were mildly correlated with the Chinese FLASQ-PD scores in the surgery-ready group (Pearson correlation = 0.399, p=0.001).

Conclusions: The Chinese FLASQ-PD, which is a simple and efficient screening tool for clinicians, was developed and initially validated in this retrospective single-center study.